organization · Reporting owner

Joyce Living Trust

Disclosed activity across 1 company

Tapewire entity: 94942
SEC CIK: 0001995778

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
bioAffinity Technologies, Inc.BIAF · Entity 8368	CO-TRUSTEE	October 01, 2023	January 25, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

bioAffinity Technologies, Inc.

Report date October 01, 2023 · Filed January 25, 2024

Jointly reported with Joyce Roby

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,867	Reported balance After 2023-10-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2023-10-01 · Grant · Acquired 11,867 · Balance 11,867 F1: Represents a grant from the Issuer to Dr. Joyce of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year
Common StockSEC Table I · non-derivative	Direct	24,535	Reported balance After 2024-01-01 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-01-01 · Grant · Acquired 12,668 · Balance 24,535 F2: Represents a grant from the Issuer to Dr. Joyce of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
Common StockSEC Table I · non-derivative	IndirectThe Joyce Living Trust	583,130	Reported balance Holding disclosure · report date 2023-10-01 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 583,130 F3: Dr. Joyce is the co-Trustee of The Joyce Living Trust (the "Trust"), together with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and disposition power with respect to the shares owned by the Trust. Dr. Joyce and Mrs. Joyce are the beneficiaries of the Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant from the Issuer to Dr. Joyce of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year

F2: Represents a grant from the Issuer to Dr. Joyce of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

F3: Dr. Joyce is the co-Trustee of The Joyce Living Trust (the "Trust"), together with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and disposition power with respect to the shares owned by the Trust. Dr. Joyce and Mrs. Joyce are the beneficiaries of the Trust.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 01, 2024 Filed Jan 25, 2024 01:52 UTC	bioAffinity Technologies, Inc. BIAF · Entity 8368	GrantCommon Stock	12,668	$1.48	$18,748.64	Disclosure SEC source: 0001493152-24-003697 · ownership.xml · nonDerivative · entry 2 Joyce Roby · CIK 0001993055 · Director Joyce Living Trust · CIK 0001995778 · CO-TRUSTEE Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,535 F2 · shares: Represents a grant from the Issuer to Dr. Joyce of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. Read SEC document
October 01, 2023 Filed Jan 25, 2024 01:52 UTC	bioAffinity Technologies, Inc. BIAF · Entity 8368	GrantCommon Stock	11,867	$1.58	$18,749.86	Disclosure SEC source: 0001493152-24-003697 · ownership.xml · nonDerivative · entry 1 Joyce Roby · CIK 0001993055 · Director Joyce Living Trust · CIK 0001995778 · CO-TRUSTEE Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,867 F1 · shares: Represents a grant from the Issuer to Dr. Joyce of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.